A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.

Completed · Phase 3

Conditions studied: Allergic Conjunctivitis

In brief

To evaluate the efficacy of Bilastine ophthalmic solution 0.6% compared to vehicle and Zaditen (Ketotifen ophthalmic solution 0.025%) for the treatment of the signs and symptoms of allergic conjunctivitis.

Key facts

Study ID

NCT03479307

Run by

Faes Farma, S.A.

People needed

228

Starts

2018-04-07

Expected to finish

2018-08-10

Last updated by the study team

2023-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• be at least 18 years old
• be willing and able to avoid all disallowed medications and contact lenses
• must have a pregnancy test if of childbearing potential
• must be able to read an eye chart from 10 feet away

You may not qualify if…

• must not have any allergies to the study medications
• must not have any ocular or non ocular condition that investigator feels will interfere with study parameters
• must not have used immunotherapy in the last 2 years
• must not have used an investigational drug or device in the past 30 days or concurrently enrolled in another investigational trial

Where it is running

• Cornea Consultants of AZ — Phoenix, Arizona, United States
• East West Eye Institute — Torrance, California, United States
• Andover Eye Associates — Andover, Massachusetts, United States
• Apex Eye — Mason, Ohio, United States
• Philadelphia Eye Associates — Philadelphia, Pennsylvania, United States
• Total Eye Care, P.A. — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.